Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:27:28.400Z.
Consensus retrieved: 2026-10-06T14:52:08.655Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:27:28.400Z.
Quote observation: 2026-10-06T19:25:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: be51af8dbdcf828107064bcf61af75d59853c311cbc38d104ed49a07c9c6f929
Forward PE Ratio (N/A) = Dated Quote Price ($11.80) / Consensus Forward EPS ($-1.50)
FORWARD PE RATIO
N/A
ORIC Pharmaceuticals, Inc.
Market Cap
$1.22B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ORIC Pharmaceuticals, Inc. (ORIC) | $1.22B | N/A |
| Cronos Group Inc. (CRON)vs › | $1.22B | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.21B | 20.33 |
| Omada Health (OMDA)vs › | $1.23B | N/A |
| Tyra Biosciences, Inc. (TYRA)vs › | $1.20B | N/A |
| MannKind Corporation (MNKD)vs › | $1.20B | N/A |
| Kardigan, Inc. (KARD)vs › | $1.26B | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.13B | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.13B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $11.80, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.50 | $-1.58 – $-1.42 | 11 | n/m |
| 2027-12-31 | $-1.66 | $-1.81 – $-1.37 | 11 | n/m |
| 2028-12-31 | $-1.78 | $-2.22 – $-1.49 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
